BAX - Baxter International Inc. Последние новости | Finranks

25.03.2026

Baxter to Host Annual Meeting of Stockholders in Virtual Format

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, c.

25.03.2026

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.

24.03.2026

EU regulator warns of shortage in Baxter's cancer treatment until early 2027

The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well ‌into the first quarter of next year.

16.03.2026

Baxter Announces CFO Transition

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade. Mr. Grade is leaving the company to prioritize family matters but will continue in an advisory capacity until April 30, 2026. Baxter has named Anita Zielinski as interim CFO, effective immediately, while the company conducts its search to fill the role. Ms. Zielinski joined Baxter in 2025 as senio.

11.03.2026

Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

06.03.2026

Sticking With Baxter At The Lows

Baxter International faces deep investor skepticism after disappointing guidance and management's decision to delay its Investor Day. Recent leadership changes and a flattened organizational structure are part of a turnaround effort, which is off to an admittedly bumpy start. But valuation is reasonable enough that BAX is a straight bet on the turnaround working.

26.02.2026

Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Видео

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
BAX	Argus	Hold	undefined >> undefined	October 31st 2025
BAX	Stifel	Hold	undefined >> $25	August 4th 2025
BAX	Goldman	Neutral	undefined >> $25	August 1st 2025
BAX	Goldman	Buy	undefined >> $42	February 26th 2025
BAX	Argus	Buy	undefined >> undefined	February 24th 2025
BAX	Barclays	Overweight	undefined >> $39	February 20th 2025

Пресс-релизы

25.03.2026

(BAX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

(BAX)

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

EU regulator warns of shortage in Baxter's cancer treatment until early 2027

Baxter Announces CFO Transition

Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Sticking With Baxter At The Lows

Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

Baxter Announces CFO Transition

Baxter Reports Fourth-Quarter 2025 Results